(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 January 2008 (31.01.2008)

PCT

(10) International Publication Number
WO 2008/014360 A2

(51) International Patent Classification:
*C07D 403/12* (2006.01) *A61K 31/4025* (2006.01)
*C07D 207/273* (2006.01)

(21) International Application Number:
PCT/US2007/074377

(22) International Filing Date: 26 July 2007 (26.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 60/834,235 | 28 July 2006 (28.07.2006) | US |
| 60/896,026 | 21 March 2007 (21.03.2007) | US |
| 11/782,742 | 25 July 2007 (25.07.2007) | US |

(71) Applicant *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; P.O. Box 4000, Route 206 and ProvinceLine Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CARTER, Percy, H.** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543 (US). **DUNCIA, John, V.** [US/US]; Route 206 & Province Line Road, Princeton, NJ 08543 (US). **MUDRYK, Boguslaw, M.** [US/US]; Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **RANDAZZO, Michael, E.** [US/US]; Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **XIAO, Zili** [CN/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543 (US). **YANG, Michael, G.** [US/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543 (US). **ZHAO, Rulin** [CA/US]; Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, NJ 08543 (US).

(74) Agents: **DUNCAN, Laurelee, A.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS




(I)

(57) Abstract: The present invention provides a novel antagonist or partial agonists/antagonist of MCP-I receptor activity: N-((lR,2S,5R)-5-(*tert*-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l- yl)cyclohexyl)acetamide, or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having an unexpected combination of desirable pharmacological characteristics. Crystalline forms of the present invention are also provided. Pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases is also an objective of this invention. The present disclosure also provides a process for preparing compounds of Formula (I), including N-((lR,2S,5R)-5-(*tert*-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide: wherein $R^1$, $R^8$, $R^9$, $R^{10}$, and "HET" are as described herein. Compounds that are useful intermediates of the process are also provided herein.

WO 2008/014360 A2